Teva Pharmaceutical Industries Revenue and Competitors
Estimated Revenue & Valuation
- Teva Pharmaceutical Industries's estimated annual revenue is currently $16.2B per year.
- Teva Pharmaceutical Industries's estimated revenue per employee is $483,251
- Teva Pharmaceutical Industries's current valuation is $10.1B. (January 2022)
Employee Data
- Teva Pharmaceutical Industries has 33585 Employees.
- Teva Pharmaceutical Industries grew their employee count by 5% last year.
Teva Pharmaceutical Industries's People
Name | Title | Email/Phone |
---|---|---|
1 | VP | Reveal Email/Phone |
2 | Assistant to VP, General Manager Teva Israel | Reveal Email/Phone |
3 | Asistente GM y VP Latinoamerica | Reveal Email/Phone |
4 | CFO Scandinavia | Reveal Email/Phone |
5 | Global VP Biosimilar Regulatory Affairs | Reveal Email/Phone |
6 | Executive Assistant to the VP NA Commercial IT | Reveal Email/Phone |
7 | CFO - Gerente Financiero | Reveal Email/Phone |
8 | Sr VP, Global Head Regulatory Affairs | Reveal Email/Phone |
9 | Chief Staff / Global Head Regulatory Planning, Metrics, Reporting and Compliance | Reveal Email/Phone |
10 | Executive Assistant to the VP Regulatory Affairs, US Generics | Reveal Email/Phone |
Teva Pharmaceutical Industries Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $43.2M | 215 | 6% | N/A | N/A |
#2 | $81.8M | 407 | 10% | N/A | N/A |
#3 | $11.7M | 58 | 0% | N/A | N/A |
#4 | $1011.8M | 5034 | -9% | N/A | N/A |
#5 | $44.8M | 223 | 1% | N/A | N/A |
#6 | $13.1M | 65 | 5% | N/A | N/A |
#7 | $16.5M | 82 | 41% | N/A | N/A |
#8 | $17.3M | 86 | -5% | N/A | N/A |
#9 | $67.9M | 338 | 23% | N/A | N/A |
#10 | $14.9M | 74 | 7% | N/A | N/A |
What Is Teva Pharmaceutical Industries?
Teva is a global generic pharmaceuticals leader and one of the top 15 pharmaceutical companies in the world. Headquartered in Israel, Teva operates in 60 countries and has 45,000 employees worldwide. Established in 1901, Teva takes great pride in its long tradition of leadership and dedication to excellence. Teva specializes in development, production and marketing of a wide range of generic and branded products, as well as active pharmaceutical ingredients (API). For over a century, Teva has maintained a distinct competitive edge through: High quality offerings Focus on customers and patients Balanced product portfolio (both generic and innovative) Integration of pharmaceutical and API activities Combination of global operations with local customer responsiveness Established international presence through a tailored network of worldwide subsidiaries Teva's business is wide and diverse, yet operations are simple and lean. This allows us to maintain leadership and always keep a competitive edge. We specialize in the development, production and marketing of generic and proprietary branded products. Our portfolio covers all major therapeutic areas and a wide variety of dosage forms. We additionally produce and supply active pharmaceutical ingredients (API) to the drug manufacturing industry worldwide.
keywords:N/AN/A
Total Funding
33585
Number of Employees
$16.2B
Revenue (est)
5%
Employee Growth %
$10.1B
Valuation
N/A
Accelerator
Teva Pharmaceutical Industries News
Teva Pharmaceutical Industries Ltd. shares fell 0.7% to $10.11 after hours Tuesday after the Food and Drug Administration sent a rejection...
The shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) are down 3.3% at $9.84 this morning, following news that the U.S. Food and Drug...
PARSIPPANY, N.J. & TEL AVIV, Israel & PARIS--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.
Teva Reports Third Quarter 2021 Financial Results Revenues of $3.9 billion GAAP diluted EPS of $0.26 Non-GAAP diluted EPS of $0.59 Cash flow generated from operating activities of $529 million Free cash flow of $795 million Full year 2021 business outlook reaffirmed Net revenues of $16.0 ...
Teva Reports Second Quarter 2021 Financial Results Revenues of $3.9 billion GAAP diluted EPS of $0.19 Non-GAAP diluted EPS of $0.59 Cash flow generated from operating activities of $218 million Free cash flow of $625 million 2021 revenue outlook revised lower to reflect ongoing impact of C ...